Treatment of Carbapenem-Resistant ESBL Klebsiella pneumoniae
For carbapenem-resistant ESBL-producing Klebsiella pneumoniae, ceftazidime-avibactam is the preferred first-line agent for serine carbapenemase producers (KPC, OXA-48), while ceftazidime-avibactam combined with aztreonam should be used for metallo-β-lactamase producers (NDM, VIM). 1
Determine the Carbapenemase Type First
The treatment strategy hinges entirely on identifying which carbapenemase enzyme your isolate produces:
For Serine Carbapenemase Producers (KPC, OXA-48)
Ceftazidime-avibactam monotherapy is strongly recommended based on observational data showing:
- 182 fewer deaths per 1000 patients (RR 0.55,95% CI 0.42-0.72)
- 307 fewer treatment failures per 1000 patients (RR 0.49,95% CI 0.34-0.70)
- 179 fewer pathogen eradication failures
- Shorter ICU length of stay 1
This represents a dramatic mortality benefit compared to older agents like polymyxins or tigecycline.
For Metallo-β-Lactamase Producers (NDM, VIM)
Ceftazidime-avibactam PLUS aztreonam combination is the treatment of choice:
- 30-day mortality: 19.2% vs 44% with other agents (p=0.007)
- Hazard ratio for mortality: 0.37 (95% CI 0.13-0.74)
- Clinical cure rate: 77.5% in critically ill patients 1
The rationale: Aztreonam remains stable against metallo-β-lactamases, while ceftazidime-avibactam protects aztreonam from other β-lactamases. This combination shows excellent in vitro synergy 1, 2.
Critical Caveat: Co-harboring NDM+OXA-48
Be aware that 55% of carbapenem-resistant K. pneumoniae may co-harbor both NDM and OXA-48, which correlates with:
- 100% resistance to ceftazidime-avibactam
- 100% resistance to aztreonam
- Near-universal resistance to aminoglycosides (>93%)
- High colistin resistance (79.8%) 2
For these extensively resistant isolates, test for synergy between ceftazidime-avibactam plus aztreonam - studies show synergistic effects in 100% of tested isolates despite individual resistance 2.
Alternative Options When New Agents Unavailable
If ceftazidime-avibactam or aztreonam are not accessible:
Combination Therapy Approach
The 2022 ESCMID guidelines recommend for severe infections:
- Two in vitro active drugs from available options (polymyxins, aminoglycosides, tigecycline, fosfomycin) 3
- Avoid monotherapy with older agents due to high failure rates
Specific Combinations with Demonstrated Synergy:
- Meropenem + colistin: 25% synergism, 15.4% additive effect 4
- Imipenem + tigecycline: 88% synergy rate - best among older combinations 4
- Colistin + tigecycline: Synergy in 86% of isolates 2
For Pneumonia Specifically
Consider intravenous colistin PLUS aerosolized colistin, which may reduce:
- Mortality by 50 per 1000 patients
- Clinical treatment failure by 77 per 1000 patients
- Days on mechanical ventilation 1
Treatment Pitfalls to Avoid
- Do NOT use levofloxacin-polymyxin B combinations - no synergy detected 4
- Do NOT rely on ceftolozane-tazobactam - 100% resistance in carbapenem-resistant K. pneumoniae 5
- Avoid polymyxin monotherapy for severe infections - high failure rates
- Do NOT assume susceptibility - 79% of carbapenem-resistant isolates were resistant to ceftazidime-avibactam in one study 5, emphasizing the need for susceptibility testing
Practical Implementation
- Immediately request carbapenemase gene testing (blaKPC, blaOXA-48, blaNDM, blaVIM, blaIMP) or phenotypic carbapenemase detection
- Order ceftazidime-avibactam and aztreonam susceptibility testing while awaiting genotype
- For empiric therapy in critically ill patients: Start ceftazidime-avibactam + aztreonam combination pending results
- De-escalate to ceftazidime-avibactam alone if only serine carbapenemases detected
- Consider synergy testing if isolate appears pan-resistant 2
The evidence strongly favors newer β-lactam combinations over polymyxin-based regimens when available, with substantially lower mortality and treatment failure rates 1, 6.